Company intelligence / Profile preview
Inipharm
Bellevue, Washington, United Statesinipharm.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 1
01
Overview
Phase 1 clinical trial data for INI-822 demonstrated plasma exposures that are anticipated to inhibit HSD17B13 with a half-life suitable for once daily oral dosing. Preclinical data showed decreased ALT levels and dose-dependent increase in hepatic phosphatidylcholines in rats, consistent with features seen in humans carrying protective forms of the HSD17B13 gene[4].
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Jubilant Biosys Limited
Beyond the preview
Go deeper on Inipharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inipharm.